Making one kilogram of active pharmaceutical ingredient can generate 25 to over 100 kilograms of waste. Most of that waste is not the reaction itself; it is solvent. Solvents typically account for 80 to 90 percent of the total mass consumed in a small molecule process, which means the single largest environmental and cost lever in API manufacturing is not the chemistry on paper, but everything poured in around it.
This is why green chemistry has moved from a corporate talking point to a core metric on the manufacturing floor. And it is why CRDMOs, who run these processes at scale on behalf of many clients, sit at the center of the effort to reduce it.
What PMI Actually Measures
Process Mass Intensity (PMI) is the total mass of everything used to make a product reagents, solvents, water, processing aids divided by the mass of product obtained. A PMI of 50 means fifty kilograms went in for every kilogram of API that came out.
PMI became the pharmaceutical industry’s preferred sustainability metric because it is simple, hard to game, and directly tied to cost. Every kilogram counted in PMI had to be purchased, handled, and eventually disposed of or recovered. The closely related E-factor measures waste per unit of product; both point at the same culprit, and both put solvents at the top of the list.
The ACS Green Chemistry Institute Pharmaceutical Roundtable, formed by major drug companies, has driven much of this work, publishing solvent selection guides, PMI benchmarks, and reaction tools that are now industry reference points.
Where the Waste Comes From
Three sources dominate solvent consumption in a typical route.
Reaction solvents. The medium the chemistry runs in, often used in large excess to keep reagents in solution and control temperature.
Workup and extraction. Washing, quenching, and phase separations consume large solvent volumes that never touch the reaction itself.
Isolation and purification. Crystallizations, chromatography, and recrystallizations: each isolation step adds solvent, and a multi-step route stacks these up quickly.
A route with six isolated intermediates carries six full cycles of reaction solvent, workup, and purification. Removing even one or two isolations can cut total solvent demand dramatically.
The Levers CRDMOs Pull
Solvent selection and substitution. The first move is replacing hazardous or hard-to-recover solvents with greener alternatives, swapping dichloromethane or DMF for 2-MeTHF, cyclopentyl methyl ether, or, where possible, water. Solvent selection guides rank options by safety, environmental impact, and recoverability, making substitution a systematic exercise rather than a guess.
Solvent recovery and recycling. At scale, distilling and reusing solvent is often the biggest single PMI reduction available. A recovered solvent stream can drop the effective PMI of a step by a large margin without changing the chemistry at all. This is where a well-equipped manufacturing site earns its keep.
Telescoping to eliminate isolations. Carrying an intermediate forward in solution without isolating and drying it removes an entire cycle of workup and purification solvent. Telescoped sequences cut PMI, shorten cycle time, and reduce handling of unstable intermediates all at once.
Catalysis over stoichiometric reagents. Replacing stoichiometric oxidants, reductants, or coupling reagents with catalytic methods reduces both reagent mass and the aqueous and organic waste generated in their workup.
Flow chemistry and process intensification. Continuous processing often runs at higher concentration and with tighter control than batch, reducing solvent volumes and enabling reactions that would otherwise require large dilution for safety.
Route redesign. The most powerful lever is also the earliest: designing a shorter, more convergent synthetic route from the start. Fewer steps mean fewer solvents, fewer isolations, and a structurally lower PMI that no amount of downstream optimization can match.
Why This Matters Commercially
Green chemistry is often framed as an environmental obligation, but the business case is just as direct. Lower solvent consumption means lower raw material costs, lower waste-disposal costs, and often faster, more robust processes. Regulators increasingly expect sustainability considerations in process development, and pharma clients now evaluate manufacturing partners on ESG performance alongside quality and cost.
For a CRDMO, PMI reduction is not a side project. It is where cost efficiency, safety, regulatory readiness, and sustainability converge in a single set of decisions made during route and process development.
The Bottom Line
The greenest kilogram of solvent is the one never used. Meaningful PMI reduction comes from decisions made early route choice, solvent selection, and how many isolations a process truly needs—reinforced later by recovery and recycling at scale.
At LAXAI Life Sciences, green chemistry principles are built into our process development from route scouting onward, alongside a focus on minimizing resource utilization and delivering sustainable solutions. The result is processes that are cleaner, more cost-effective, and easier to scale advancing your program while reducing its footprint, within a fully integrated CRDMO framework.
